Diabetes Mellitus Liver dysfunction
Conditions
Interventions
Group A: sitagliptin 50mg QD
Group B: repaglinide 0.25mg TID
Sponsors
Osaka Medical College Hospital
Osaka Medical College Hospital, Ishikiriseiki Hospital, Shiroyama Hospital, Sugimoto Clinic, Seikeikai Hospital, Taisyou Hospital, First Towakai Hospital, Hanwasumiyosi General Hospital, Hokusetsu General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who have fatty liver by picture evaluation ( abdomen echo check, abdomen CT inspection) 2)Patients who have abnormalities in AST, ALT, or gamma-GTP 3)Patients who have abnormalities in TG, T-CHO, or FFA 4)Patient who have abnormalities in either IV type collagen S or ferritin Patients who fulfilled above 1) and 2)as indispensable condition, and either 3) or 4), or both 3) and 4)
Exclusion criteria
Exclusion criteria: 1) Patients who have renal dysfunction 2) Patients whose medicine or its dosage changed during the study duration if antihypertensive drug, antilipidemial drug or medicine which effects on other liver functions is used. 3) Patients who are considered inappropriate as a target patient by a physician-in-charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NAFIC score(Ferritin, IRI, Type4collagen 7s) | — |
Secondary
| Measure | Time frame |
|---|---|
| diagnostic imaging, blood test , adiponecti, GLP-1(Active form), free fatty acid | — |
Countries
Japan
Contacts
Public ContactShinya Fukunishi
Osaka Medical College Hospital Second internal medicine
Outcome results
None listed